Correlation between PD-L1 and Ki-67 Expression at various T-stage Clear Cell Renal Cell Carcinomas
Renal cell carcinoma (RCC) is a malignant neoplasm originating from renal epithelium, with the clear cell renal cell carcinoma (ccRCC)being the most common type (80%) and the most common cause of death among other types of kidney cancer. Pathological stage is an important parameter that affects ccRC...
Gespeichert in:
Veröffentlicht in: | Research journal of pharmacy and technology 2024-01, Vol.17 (1), p.109-114 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 114 |
---|---|
container_issue | 1 |
container_start_page | 109 |
container_title | Research journal of pharmacy and technology |
container_volume | 17 |
creator | Setijo Rahaju, Anny Rahniayu, Alphania Hary Kusumastuti, Etty Adi Wiratama, Priangga Kusumadewi P. Thaib, Pamela Takaria, Mimi |
description | Renal cell carcinoma (RCC) is a malignant neoplasm originating from renal epithelium, with the clear cell renal cell carcinoma (ccRCC)being the most common type (80%) and the most common cause of death among other types of kidney cancer. Pathological stage is an important parameter that affects ccRCC survival, followed by nuclear grade. Pathological staging of RCC according to the AJCC (American Joint Committee on Cancer) TNM system 8th edition is based on local extension of the main tumor (T), involvement of lymph node (N), and metastasis (M). Ki-67 is a marker of proliferation used to assess tumor grade. High Ki-67 correlates with poor prognosis, advanced clinical and pathological features, thus Ki-67 can be used as a biomarker in the management of RCC.Ki-67 is routinely used to see the proliferation index in various cases of malignancy, but not in kidney malignancy. Programmed death ligand 1 (PD-L1) acts as a negative regulator of T cell-mediated anti-tumor immune responses. PD-L1 is expressed on T cells, B cells, macrophages, dendritic cells, endothelial cells and in various tumor cells including ccRCC. This study aims to determine the correlation between the expression of PD-L1 and Ki-67 in various T-stage clear cell renal cell carcinomas. Material and Method: This was an observational analytical study with cross-sectional approach toward 52 cases of ccRCC whose diagnosis was made histopathologically at the Anatomical Pathology Installation of Dr. Soetomo General Academic Hospital Surabaya from January 2014 to December 2020. Immunohistochemical stainingwas carried out using Ki-67 and PD-L1 antibodies, followed by an assessment using a scoring system. T-stage data were obtained from the patients’ medical recordswhich were then analyzed statistically with the Spearman test. Result: The study included 52 cases of ccRCC obtained from nephrectomy specimens at RSUD dr. Soetomo between 2014–2020. The age distribution of the subjects was 29–69 years and the mean and median age was 53 years. The ratio of male patients compared to female patients was 2.5:1. The majority was stage T2 (50%). Statistical test results showed no correlation between the expression of PD-L1 and Ki-67 in various T-stage clear cell renal cell carcinomas (p=0.965 and p=0.680). Conclusion: This study showed no correlation between the expression of PD-L1 and Ki-67 in various T-stage clear cell renal cell carcinomas. Nonetheless PD-L1 can be considered as an important biomarker with a poore |
doi_str_mv | 10.52711/0974-360X.2024.00017 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2974586277</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2974586277</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1917-255209e3ddaf04a8f5bff3a92a6bf3eada4be7c94b06656cff0d42ed1762c95f3</originalsourceid><addsrcrecordid>eNo9kF1LwzAUhoMoOOZ-ghDwujNJ89FeSp0fOFBkgnfhtD2Rjq6ZSefHv7fdZFfn5fDw8vIQcsnZXAnD-TXLjUxSzd7nggk5Z4xxc0Imx_fpMfPsnMxiXA8I05kSMpuQsvAhYAt94ztaYv-N2NGX22TJKXQ1fWoSbejiZxswxhGBnn5BaPwu0lUSe_hAWrQIgRbYtvQVO2gPsYBQNZ3fQLwgZw7aiLP_OyVvd4tV8ZAsn-8fi5tlUvGcm0QoJViOaV2DYxIyp0rnUsgF6NKlCDXIEk2Vy5JprXTlHKulwJobLapcuXRKrg692-A_dxh7u_a7MAyKVgwCVKaFMQOlDlQVfIwBnd2GZgPh13Jm90btqMuO6uxo1O6Npn9NHmgk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2974586277</pqid></control><display><type>article</type><title>Correlation between PD-L1 and Ki-67 Expression at various T-stage Clear Cell Renal Cell Carcinomas</title><source>EZB Electronic Journals Library</source><creator>Setijo Rahaju, Anny ; Rahniayu, Alphania ; Hary Kusumastuti, Etty ; Adi Wiratama, Priangga ; Kusumadewi P. Thaib, Pamela ; Takaria, Mimi</creator><creatorcontrib>Setijo Rahaju, Anny ; Rahniayu, Alphania ; Hary Kusumastuti, Etty ; Adi Wiratama, Priangga ; Kusumadewi P. Thaib, Pamela ; Takaria, Mimi</creatorcontrib><description>Renal cell carcinoma (RCC) is a malignant neoplasm originating from renal epithelium, with the clear cell renal cell carcinoma (ccRCC)being the most common type (80%) and the most common cause of death among other types of kidney cancer. Pathological stage is an important parameter that affects ccRCC survival, followed by nuclear grade. Pathological staging of RCC according to the AJCC (American Joint Committee on Cancer) TNM system 8th edition is based on local extension of the main tumor (T), involvement of lymph node (N), and metastasis (M). Ki-67 is a marker of proliferation used to assess tumor grade. High Ki-67 correlates with poor prognosis, advanced clinical and pathological features, thus Ki-67 can be used as a biomarker in the management of RCC.Ki-67 is routinely used to see the proliferation index in various cases of malignancy, but not in kidney malignancy. Programmed death ligand 1 (PD-L1) acts as a negative regulator of T cell-mediated anti-tumor immune responses. PD-L1 is expressed on T cells, B cells, macrophages, dendritic cells, endothelial cells and in various tumor cells including ccRCC. This study aims to determine the correlation between the expression of PD-L1 and Ki-67 in various T-stage clear cell renal cell carcinomas. Material and Method: This was an observational analytical study with cross-sectional approach toward 52 cases of ccRCC whose diagnosis was made histopathologically at the Anatomical Pathology Installation of Dr. Soetomo General Academic Hospital Surabaya from January 2014 to December 2020. Immunohistochemical stainingwas carried out using Ki-67 and PD-L1 antibodies, followed by an assessment using a scoring system. T-stage data were obtained from the patients’ medical recordswhich were then analyzed statistically with the Spearman test. Result: The study included 52 cases of ccRCC obtained from nephrectomy specimens at RSUD dr. Soetomo between 2014–2020. The age distribution of the subjects was 29–69 years and the mean and median age was 53 years. The ratio of male patients compared to female patients was 2.5:1. The majority was stage T2 (50%). Statistical test results showed no correlation between the expression of PD-L1 and Ki-67 in various T-stage clear cell renal cell carcinomas (p=0.965 and p=0.680). Conclusion: This study showed no correlation between the expression of PD-L1 and Ki-67 in various T-stage clear cell renal cell carcinomas. Nonetheless PD-L1 can be considered as an important biomarker with a poorer prognosis and aggressive clinicopathological findings in patients with RCC.</description><identifier>ISSN: 0974-3618</identifier><identifier>EISSN: 0974-360X</identifier><identifier>EISSN: 0974-306X</identifier><identifier>DOI: 10.52711/0974-360X.2024.00017</identifier><language>eng</language><publisher>Raipur: A&V Publications</publisher><subject>Age ; Antibodies ; Biomarkers ; Chemotherapy ; Dendritic cells ; Females ; Genetic disorders ; Kidney cancer ; Ligands ; Lymphatic system ; Medical prognosis ; Medical records ; Metastasis ; Pathology ; Tumors</subject><ispartof>Research journal of pharmacy and technology, 2024-01, Vol.17 (1), p.109-114</ispartof><rights>Copyright A&V Publications Jan 2024</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1917-255209e3ddaf04a8f5bff3a92a6bf3eada4be7c94b06656cff0d42ed1762c95f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Setijo Rahaju, Anny</creatorcontrib><creatorcontrib>Rahniayu, Alphania</creatorcontrib><creatorcontrib>Hary Kusumastuti, Etty</creatorcontrib><creatorcontrib>Adi Wiratama, Priangga</creatorcontrib><creatorcontrib>Kusumadewi P. Thaib, Pamela</creatorcontrib><creatorcontrib>Takaria, Mimi</creatorcontrib><title>Correlation between PD-L1 and Ki-67 Expression at various T-stage Clear Cell Renal Cell Carcinomas</title><title>Research journal of pharmacy and technology</title><description>Renal cell carcinoma (RCC) is a malignant neoplasm originating from renal epithelium, with the clear cell renal cell carcinoma (ccRCC)being the most common type (80%) and the most common cause of death among other types of kidney cancer. Pathological stage is an important parameter that affects ccRCC survival, followed by nuclear grade. Pathological staging of RCC according to the AJCC (American Joint Committee on Cancer) TNM system 8th edition is based on local extension of the main tumor (T), involvement of lymph node (N), and metastasis (M). Ki-67 is a marker of proliferation used to assess tumor grade. High Ki-67 correlates with poor prognosis, advanced clinical and pathological features, thus Ki-67 can be used as a biomarker in the management of RCC.Ki-67 is routinely used to see the proliferation index in various cases of malignancy, but not in kidney malignancy. Programmed death ligand 1 (PD-L1) acts as a negative regulator of T cell-mediated anti-tumor immune responses. PD-L1 is expressed on T cells, B cells, macrophages, dendritic cells, endothelial cells and in various tumor cells including ccRCC. This study aims to determine the correlation between the expression of PD-L1 and Ki-67 in various T-stage clear cell renal cell carcinomas. Material and Method: This was an observational analytical study with cross-sectional approach toward 52 cases of ccRCC whose diagnosis was made histopathologically at the Anatomical Pathology Installation of Dr. Soetomo General Academic Hospital Surabaya from January 2014 to December 2020. Immunohistochemical stainingwas carried out using Ki-67 and PD-L1 antibodies, followed by an assessment using a scoring system. T-stage data were obtained from the patients’ medical recordswhich were then analyzed statistically with the Spearman test. Result: The study included 52 cases of ccRCC obtained from nephrectomy specimens at RSUD dr. Soetomo between 2014–2020. The age distribution of the subjects was 29–69 years and the mean and median age was 53 years. The ratio of male patients compared to female patients was 2.5:1. The majority was stage T2 (50%). Statistical test results showed no correlation between the expression of PD-L1 and Ki-67 in various T-stage clear cell renal cell carcinomas (p=0.965 and p=0.680). Conclusion: This study showed no correlation between the expression of PD-L1 and Ki-67 in various T-stage clear cell renal cell carcinomas. Nonetheless PD-L1 can be considered as an important biomarker with a poorer prognosis and aggressive clinicopathological findings in patients with RCC.</description><subject>Age</subject><subject>Antibodies</subject><subject>Biomarkers</subject><subject>Chemotherapy</subject><subject>Dendritic cells</subject><subject>Females</subject><subject>Genetic disorders</subject><subject>Kidney cancer</subject><subject>Ligands</subject><subject>Lymphatic system</subject><subject>Medical prognosis</subject><subject>Medical records</subject><subject>Metastasis</subject><subject>Pathology</subject><subject>Tumors</subject><issn>0974-3618</issn><issn>0974-360X</issn><issn>0974-306X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNo9kF1LwzAUhoMoOOZ-ghDwujNJ89FeSp0fOFBkgnfhtD2Rjq6ZSefHv7fdZFfn5fDw8vIQcsnZXAnD-TXLjUxSzd7nggk5Z4xxc0Imx_fpMfPsnMxiXA8I05kSMpuQsvAhYAt94ztaYv-N2NGX22TJKXQ1fWoSbejiZxswxhGBnn5BaPwu0lUSe_hAWrQIgRbYtvQVO2gPsYBQNZ3fQLwgZw7aiLP_OyVvd4tV8ZAsn-8fi5tlUvGcm0QoJViOaV2DYxIyp0rnUsgF6NKlCDXIEk2Vy5JprXTlHKulwJobLapcuXRKrg692-A_dxh7u_a7MAyKVgwCVKaFMQOlDlQVfIwBnd2GZgPh13Jm90btqMuO6uxo1O6Npn9NHmgk</recordid><startdate>20240101</startdate><enddate>20240101</enddate><creator>Setijo Rahaju, Anny</creator><creator>Rahniayu, Alphania</creator><creator>Hary Kusumastuti, Etty</creator><creator>Adi Wiratama, Priangga</creator><creator>Kusumadewi P. Thaib, Pamela</creator><creator>Takaria, Mimi</creator><general>A&V Publications</general><scope>AAYXX</scope><scope>CITATION</scope><scope>04Q</scope><scope>04S</scope><scope>04W</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>20240101</creationdate><title>Correlation between PD-L1 and Ki-67 Expression at various T-stage Clear Cell Renal Cell Carcinomas</title><author>Setijo Rahaju, Anny ; Rahniayu, Alphania ; Hary Kusumastuti, Etty ; Adi Wiratama, Priangga ; Kusumadewi P. Thaib, Pamela ; Takaria, Mimi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1917-255209e3ddaf04a8f5bff3a92a6bf3eada4be7c94b06656cff0d42ed1762c95f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Age</topic><topic>Antibodies</topic><topic>Biomarkers</topic><topic>Chemotherapy</topic><topic>Dendritic cells</topic><topic>Females</topic><topic>Genetic disorders</topic><topic>Kidney cancer</topic><topic>Ligands</topic><topic>Lymphatic system</topic><topic>Medical prognosis</topic><topic>Medical records</topic><topic>Metastasis</topic><topic>Pathology</topic><topic>Tumors</topic><toplevel>online_resources</toplevel><creatorcontrib>Setijo Rahaju, Anny</creatorcontrib><creatorcontrib>Rahniayu, Alphania</creatorcontrib><creatorcontrib>Hary Kusumastuti, Etty</creatorcontrib><creatorcontrib>Adi Wiratama, Priangga</creatorcontrib><creatorcontrib>Kusumadewi P. Thaib, Pamela</creatorcontrib><creatorcontrib>Takaria, Mimi</creatorcontrib><collection>CrossRef</collection><collection>India Database</collection><collection>India Database: Business</collection><collection>India Database: Science & Technology</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>Research journal of pharmacy and technology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Setijo Rahaju, Anny</au><au>Rahniayu, Alphania</au><au>Hary Kusumastuti, Etty</au><au>Adi Wiratama, Priangga</au><au>Kusumadewi P. Thaib, Pamela</au><au>Takaria, Mimi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Correlation between PD-L1 and Ki-67 Expression at various T-stage Clear Cell Renal Cell Carcinomas</atitle><jtitle>Research journal of pharmacy and technology</jtitle><date>2024-01-01</date><risdate>2024</risdate><volume>17</volume><issue>1</issue><spage>109</spage><epage>114</epage><pages>109-114</pages><issn>0974-3618</issn><eissn>0974-360X</eissn><eissn>0974-306X</eissn><abstract>Renal cell carcinoma (RCC) is a malignant neoplasm originating from renal epithelium, with the clear cell renal cell carcinoma (ccRCC)being the most common type (80%) and the most common cause of death among other types of kidney cancer. Pathological stage is an important parameter that affects ccRCC survival, followed by nuclear grade. Pathological staging of RCC according to the AJCC (American Joint Committee on Cancer) TNM system 8th edition is based on local extension of the main tumor (T), involvement of lymph node (N), and metastasis (M). Ki-67 is a marker of proliferation used to assess tumor grade. High Ki-67 correlates with poor prognosis, advanced clinical and pathological features, thus Ki-67 can be used as a biomarker in the management of RCC.Ki-67 is routinely used to see the proliferation index in various cases of malignancy, but not in kidney malignancy. Programmed death ligand 1 (PD-L1) acts as a negative regulator of T cell-mediated anti-tumor immune responses. PD-L1 is expressed on T cells, B cells, macrophages, dendritic cells, endothelial cells and in various tumor cells including ccRCC. This study aims to determine the correlation between the expression of PD-L1 and Ki-67 in various T-stage clear cell renal cell carcinomas. Material and Method: This was an observational analytical study with cross-sectional approach toward 52 cases of ccRCC whose diagnosis was made histopathologically at the Anatomical Pathology Installation of Dr. Soetomo General Academic Hospital Surabaya from January 2014 to December 2020. Immunohistochemical stainingwas carried out using Ki-67 and PD-L1 antibodies, followed by an assessment using a scoring system. T-stage data were obtained from the patients’ medical recordswhich were then analyzed statistically with the Spearman test. Result: The study included 52 cases of ccRCC obtained from nephrectomy specimens at RSUD dr. Soetomo between 2014–2020. The age distribution of the subjects was 29–69 years and the mean and median age was 53 years. The ratio of male patients compared to female patients was 2.5:1. The majority was stage T2 (50%). Statistical test results showed no correlation between the expression of PD-L1 and Ki-67 in various T-stage clear cell renal cell carcinomas (p=0.965 and p=0.680). Conclusion: This study showed no correlation between the expression of PD-L1 and Ki-67 in various T-stage clear cell renal cell carcinomas. Nonetheless PD-L1 can be considered as an important biomarker with a poorer prognosis and aggressive clinicopathological findings in patients with RCC.</abstract><cop>Raipur</cop><pub>A&V Publications</pub><doi>10.52711/0974-360X.2024.00017</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0974-3618 |
ispartof | Research journal of pharmacy and technology, 2024-01, Vol.17 (1), p.109-114 |
issn | 0974-3618 0974-360X 0974-306X |
language | eng |
recordid | cdi_proquest_journals_2974586277 |
source | EZB Electronic Journals Library |
subjects | Age Antibodies Biomarkers Chemotherapy Dendritic cells Females Genetic disorders Kidney cancer Ligands Lymphatic system Medical prognosis Medical records Metastasis Pathology Tumors |
title | Correlation between PD-L1 and Ki-67 Expression at various T-stage Clear Cell Renal Cell Carcinomas |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T19%3A05%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Correlation%20between%20PD-L1%20and%20Ki-67%20Expression%20at%20various%20T-stage%20Clear%20Cell%20Renal%20Cell%20Carcinomas&rft.jtitle=Research%20journal%20of%20pharmacy%20and%20technology&rft.au=Setijo%20Rahaju,%20Anny&rft.date=2024-01-01&rft.volume=17&rft.issue=1&rft.spage=109&rft.epage=114&rft.pages=109-114&rft.issn=0974-3618&rft.eissn=0974-360X&rft_id=info:doi/10.52711/0974-360X.2024.00017&rft_dat=%3Cproquest_cross%3E2974586277%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2974586277&rft_id=info:pmid/&rfr_iscdi=true |